After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Neurocrine Biosciences, Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Drug Manufacturers – Specialty & Generic industry. The current market capitalization of Neurocrine Biosciences, Inc. is $13.23B. A total of 1.03 million shares were traded on the day, compared to an average of 878.50K shares.
In the most recent transaction, Delaet Ingrid sold 272 shares of NBIX for 137.30 per share on Apr 01 ’24. After the transaction, the Chief Regulatory Officer now owns 7,507 company shares. In a previous transaction on Mar 21 ’24, Delaet Ingrid sold 5,000 shares at 145.06 per share. NBIX shares that Chief Regulatory Officer owns now total 7,507.
Among the insiders who sold shares, BENEVICH ERIC disposed of 75,000 shares on Mar 14 ’24 at a per-share price of $139.38. This resulted in the Chief Commercial Officer holding 40,778 shares of NBIX after the transaction. In another insider transaction, MORROW GEORGE J sold 40,000 shares at $139.42 per share on Mar 14 ’24. Company shares held by the Director now total 0.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, NBIX has a high of $148.37 and a low of $89.04.
As of this writing, NBIX has an earnings estimate of $Nurix Therapeutics, Inc. per share for the current quarter. EPS was calculated based on a consensus of Neurocrine Biosciences, Inc. estimates, with a high estimate of $NASCENT BIOTECH INC per share and a lower estimate of $Nanobiotix S.A..
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. NBIX’s latest balance sheet shows that the firm has $711.30M in Cash & Short Term Investments as of fiscal 2021. There were $440.40M in debt and $245.80M in liabilities at the time. Its Book Value Per Share was $22.61, while its Total Shareholder’s Equity was $1.37B.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for NBIX is Buy with a score of 4.48.
